Sumitomo Pharma Co

Sumitomo Pharma Co EPS

The Earnings per Share (EPS) of Sumitomo Pharma Co (4506.T) as of Nov 20, 2026 is 238.80 JPY. In the previous year, Earnings per Share (EPS) was 59.49 JPY — a change of 301.43% (higher).

EPS

238.80JPY

YoY

301.43%

Last updated:

Earnings per Share (EPS) of Sumitomo Pharma Co is 2026 238.80 JPY. Earnings per Share (EPS) of Sumitomo Pharma Co was 2025 59.49 JPY. It decreases by 301.43% higher compared to the previous year.

The Sumitomo Pharma Co EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2024
-792.79 JPY
Jan 1, 2025
59.49 JPY
Jan 1, 2026
238.80 JPY
Jan 1, 2027 (e)
220.31 JPY
Jan 1, 2028 (e)
220.98 JPY
Jan 1, 2029 (e)
172.64 JPY
Jan 1, 2030 (e)
151.16 JPY
Jan 1, 2031 (e)
75.90 JPY
The Sumitomo Pharma Co EPS history
YEAREPSYoY
est75.90JPY-49.79%
est151.16JPY-12.44%
est172.64JPY-21.87%
est220.98JPY+0.30%
est220.31JPY-7.74%
238.80JPY+301.43%
59.49JPY-107.50%
-792.79JPY+322.71%
-187.55JPY-232.08%
141.99JPY+0.35%
141.51JPY+37.95%
102.58JPY-16.19%
122.40JPY-9.02%
134.53JPY+70.67%
78.82JPY+26.80%
62.16JPY+59.88%
38.88JPY-23.00%
50.49JPY+99.74%
25.28JPY+16.39%
21.72JPY-48.62%
42.27JPY-19.86%
52.75JPY+4.86%
50.31JPY-21.90%
64.41JPY+27.51%
50.51JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sumitomo Pharma Co Stock analysis

What does Sumitomo Pharma Co do? Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sumitomo Pharma Co stock

Earnings per Share (EPS) of Sumitomo Pharma Co is 238.80 JPY in 2026.

Earnings per Share (EPS) of Sumitomo Pharma Co changed from 59.49 JPY to 238.80 JPY, representing a 301.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Sumitomo Pharma Co since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sumitomo Pharma Co

All Key Metrics — Sumitomo Pharma Co